Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Moen, Ingrid ^a,b   Tronstad, Karl J ^a   Kolmannskog, Odd ^a   Salvesen, Gerd S ^a   Reed, Rolf K ^a   Stuhr, Linda E B ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; OXYGEN; ANTINEOPLASTIC ANTIMETABOLITE; REACTIVE OXYGEN METABOLITE;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG UPTAKE; EXTRACELLULAR MATRIX; FEMALE; HYPERBARIC OXYGEN; HYPEROXIA; IMMUNOHISTOCHEMISTRY; INTERSTITIAL FLUID; INTERSTITIUM; NONHUMAN; OXYGENATION; RAT; STROMA; TUMOR VOLUME; ANIMAL; BLOOD VOLUME; EVALUATION; EXPERIMENTAL NEOPLASM; EXTRACELLULAR FLUID; LYMPH; METABOLISM; OSMOTIC PRESSURE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STROMA CELL;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD VOLUME; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR FLUID; FEMALE; FLUOROURACIL; HYPERBARIC OXYGENATION; HYPEROXIA; LYMPH; MAMMARY NEOPLASMS, EXPERIMENTAL; OSMOTIC PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; STROMAL CELLS;

EID: 74749099799     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-446     Document Type: Article

References (50)

1. Hoogsteen IJ, Marres HA, Kogel AJ, Kaanders JH. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol (R Coll Radiol) 2007, 19(6):385-396.
2. Harrison L, Blackwell K. Hypoxia and anemia:factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004, 9(Suppl 5):31-40. 10.1634/theoncologist.9-90005-31, 15591420.
3. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Research 1987, 47(12):3039-3051.
4. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK. Interstitial hypertension in human breast and colorectal tumors. Cancer Research 1992, 52:6371-6374.
5. Nathanson SD, Nelson L. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann Surg Oncol 1994, 1(4):333-338.
6. Gullino PM, Clark SH, Grantham FH. The interstitial fluid of solid tumors. Cancer Research 1964, 24:780-797.
7. Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand J Clin Lab Invest 1982, 42(2):159-164. 10.3109/00365518209168067, 6813944.
8. Heldin NE, Rubin K, Pietras K, Östman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev 2004, 4:806-813.
9. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Research 2000, 60:2497-2503.
10. Znati CA, Rosenstein M, McKee TD, Brown E, Turner D, Bloomer WD, Watkins S, Jain RK, Boucher Y. Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin Cancer Research 2003, 9:5508-5513.
11. Eikenes L, Bruland T, Brekken C, de Lange Davies C. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Caner Research 2004, 64:4768-4773.
12. Kinoshita Y, Kohshi K, Kunugita N, Tosaki T, Yokota A. Preservation of tumor oxygen after hyperbaric oxygenation monotored by magnetic resonance imaging. Brit J of Cancer 2000, 82:88-92.
13. Takiguchi N, Saito N, Nunomura M, Kouda K, Oda K, Furuyama N, Nakajima N. Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in induvidual organs. Cancer Chemother Pharmacol 2001, 47(1):11-14. 10.1007/s002800000190, 11221954.
14. Stuhr LE, Iversen VV, Straume O, Maehle BO, Reed RK. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer Lett 2004, 210(1):35-40. 10.1016/j.canlet.2004.02.012, 15172118.
15. Al-Waili NS, Betler G, Beale J, Hamilton RW, Lee BY, Lucas P. Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med Sci Monit 2005, 11(9):RA279-289.
16. Petre PM, Baciewicz FA, Tigan S, Spears JR. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. J Thorac Cardiovasc Surg 2003, 125(1):85-95. discussion 95, 10.1067/mtc.2003.90, 12538989.
17. Teicher BA, Crawford JM, Holden SA, Cathcart KN. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Res 1987, 47(19):5036-5041.
18. Alagoz T, Buller RE, Anderson B, Terrell KL, Squatrito RC, Niemann TH, Tatman DJ, Jebson P. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer 1995, 75(9):2313-2322. 10.1002/1097-0142(19950501)75:9<2313::AID-CNCR2820750921>3.0.CO;2-6, 7536123.
19. Raa A, Stansberg C, Steen VM, Bjerkvig R, Reed RK, Stuhr L. Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer 2007, 7(1). 10.1186/1471-2407-7-23, 1797183, 17263869.
20. Stuhr LB, Raa A, Øyan AM, Kalland KH, Sakariassen PO, Petersen K, Bjerkvig R, Reed RK. Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. J Neurooncology 2007, 85(2):191-202.
21. Moen I, Oyan AM, Kalland KH, Tronstad KJ, Akslen LA, Chekenya M, Sakariassen PO, Reed RK, Stuhr LE. Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One 2009, 4(7):e6381. 10.1371/journal.pone.0006381, 2712688, 19636430.
22. Schmelz M, Luz O, Averbeck B, Bickel A. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neuroscience Letters 1997, 230:117-120. 10.1016/S0304-3940(97)00494-1, 9259478.
23. Iversen VV, Brønstad A, Gjerde E-AB, Reed RK. Continuous measurements of plasma protein extravasation with microdialysis after various infalmmatory challenges in rat and mouse skin. Am J Physiol Heart Circ Physiol 2004, 286:H108-H112. 10.1152/ajpheart.00542.2003, 12946931.
24. Fadnes HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvascular Research 1977, 14(27):27-36. 10.1016/0026-2862(77)90138-8, 895543.
25. Woessner JR. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Archives of biochemistry and biophysics 1961, 93:440-447. 10.1016/0003-9861(61)90291-0, 13786180.
26. Reed RK, Lepsøe S, Wiig H. Interstitial exclusion of albumin in rat dermis and subcutis in over- and dehydration. Am J Physiol 1989, 257:H1819-1827.
27. Kalns J, Krock L, Piepmeier E. The effect of hyperbaric oxygen on growth and chemosensitivity of metastatic prostate cancer. Anticancer Res 1998, 18(1A):363-367.
28. Daruwalla J, Christophi C. Hyperbaric oxygen therapy for malignancy: A review. World Journal of Surgery 2006, 30(12):2112-2131. 10.1007/s00268-006-0190-6, 17102915.
29. Emerich DF, Dean RL, Snodgrass P, Lafreniere D, Agostino M, Wiens T, Xiong H, Hasler B, Marsh J, Pink M, Kim BS, Perdomo B, Bartus RT. Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther 2001, 296(2):632-641.
30. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Research 2002, 62(19):5476-5484.
31. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, Sjoquist M, Ahlstrom H, Reed RK, Rubin K, Lammerts E, Roswall P, Gotwals PJ, Koteliansky VE, Heldin NE. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Faseb J 2003, 17(12):1756-1758.
32. Stuhr LEB, Salnikov AV, Iversen VV, Salvesen G, Rubin K, Reed RK. High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces growth and augments the effects of 5-fluorouracil on dimethyl-alpha-benzanthracene-induced mammary tumors in rats. Scand J Clin Lab Invest 2006, 66:477-486. 10.1080/00365510600788332, 17000555.
33. Davies E, Clarke C, Hopkins A. Malignant cerebral glioma-I: Survival, disability, and morbidity after radiotherapy. BMJ 1996, 313:1507-1512. 2353065, 8978224.
34. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999, 290(2):871-880.
35. Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release 2002, 78(1-3):81-95. 10.1016/S0168-3659(01)00488-6, 11772451.
36. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Cont Release 1998, 53(1-3):49-67.
37. Brizel DM, Lin S, Johnson JL, Brooks J, Dewhirst MW, Piantadosi CA. The mechanisms by which hyperbaric oxygen and carbogen improve tumor oxygenation. Brit J of Cancer 1995, 72(5):1120-1124.
38. Reed RK, Berg A, Gjerde EA, Rubin K. Control of interstitial fluid pressure: role of beta1-integrins. Semin Nephrol 2001, 21(3):222-230. 10.1053/snep.2001.21646, 11320485.
39. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001, 7(9):987-989. 10.1038/nm0901-987, 11533692.
40. Lee C-G, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewich M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y. Anti-Vascular Endothelial Growth Factor treatment augments tumor radiation responce under normoxic or hypoxic conditions. Cancer Research 2000, 60:5565-5570.
41. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenetic therapy on interstitial hypertension, peritumor edema, lymphatic metastasis: insights from a mathematical model. Cancer Research 2007, 67(6):2729-2735. 10.1158/0008-5472.CAN-06-4102, 17363594.
42. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research 2004, 1(64):3731-3736.
43. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005, 437(7058):497-504. 10.1038/nature03987, 16177780.
44. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006, 66(3):1434-1445. 10.1158/0008-5472.CAN-05-0923, 16452199.
45. Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK. Combined Vascular Endothelial Growth Factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice. Seminars in oncology 2006, 33:S35-S40. 10.1053/j.seminoncol.2006.08.007, 2686124, 17145523.
46. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. The American physiological society 1993, 73(1):1-78.
47. Wiig H, Rubin K, Reed RK, Tveit E, Hultborn R, Weiss L. New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences. Evaluation of methodologies for measurement of interstitial fluid pressure (Pif): physiological implications of recent Pi data. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Acta Anaesthesiol Scand 2003, 47(2):111-121. 10.1034/j.1399-6576.2003.00050.x, 12631039.
48. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvascular Research 2007, Article, 2100036, 17560615.
49. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 2007, 401(1):1-11. 10.1042/BJ20061131, 17150040.
50. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4(11):891-899. 10.1038/nrc1478, 15516961.